Chengdu Easton Biopharmaceuticals' (SHA:688513) two products won pre-bids under China's drug procurement program, according to a Tuesday filing with the Shanghai bourse.
The drugs involved include nicarpidine hydrochloride injection for emergency hypertension treatment and its bisoprolol and amlodipine tablets, also for hypertension.